New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
11:58 EDTHLF, RPRX, NKTR, SPPI, CTXSStocks with increasing implied volatility; HLF RPRX NKTR SPPI CTXS
News For HLF;RPRX;NKTR;SPPI;CTXS From The Last 14 Days
Check below for free stories on HLF;RPRX;NKTR;SPPI;CTXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 18, 2014
07:19 EDTRPRXRepros Therapeutics sell-off overdone, says Brean Capital
Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.
07:07 EDTSPPISpectrum out-licenses rights for Greater China to CASI for three drugs
Subscribe for More Information
07:05 EDTSPPISpectrum out-licenses rights for Greater China to CASI for three drugs
Subscribe for More Information
07:00 EDTRPRXRepros Therapeutics price target lowered to $13 from $24 at Piper Jaffray
Subscribe for More Information
06:10 EDTRPRXFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information
September 16, 2014
15:32 EDTCTXSCitrix acquires Android and iOS virtualization start-up, TechCrunch reports
Citrix has acquired a start-up, Virtual, that claims to be able to virtualize both Android and iOS well enough to act as an environment for bug testing and hardware emulation, reported TechCrunch, citing "a reliable source." Reference Link
14:33 EDTNKTRNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
13:22 EDTNKTRNektar approval improves risk/reward, says Piper Jaffray
Piper Jaffray says today's FDA approval of Movantik improves the risk/reward on shares of Nektar. Piper expects Movantik to be one of a series of successes for the company and reiterates an Overweight rating on the stock with a $20 price target. The firm says the post-marketing study required by the FDA to evaluate potential cardiovascular risks was expected.
13:17 EDTNKTRNektar up 3% after FDA approves Movantik for treatment of OIC
Subscribe for More Information
12:37 EDTNKTRNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
10:19 EDTNKTRFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
10:11 EDTNKTRNektar trading halted, pending news
08:00 EDTNKTRFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:02 EDTSPPISpectrum issued new patent for Beleodaq for injection
Spectrum Pharmaceuticals announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8835501, which covers Beleodaq for Injection on September 16, 2014 with patent term adjustment from May 2026 to October 2027. In addition to the existing patent, covering the chemical entity of Beleodaq, this new patent covers the formulation of the product, strengthening and expanding significantly its industrial property protection.
September 15, 2014
12:14 EDTHLFHerbalife expands partnership with American Youth Soccer Organization
Subscribe for More Information
08:13 EDTCTXSCitrix price target raised ot $80 from $70 at Mizuho
Subscribe for More Information
September 14, 2014
16:17 EDTHLFHerbalife near settlement with former distributors, NY Post says
Herbalife is close to reaching a settlement with five former distributors that allege the nutrition company is a pyramid scheme and has victimized thousands, says the NY Post. Reference Link
September 10, 2014
07:22 EDTCTXSCitrix coverage assumed with a Buy at MKM Partners
Target $85.
September 9, 2014
07:01 EDTSPPISpectrum to advance SPI-2013 to Phase 3 trials
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use